Phase 2 N=122 Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients
HIV-1 Infection
Primary: Virologic Status at Week 24 — 108; 5; 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=855 A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
Clostridium Difficile Associated Disease
Primary: Day 1, 8 and 30 Regimen: Percentage of Participants Achieving Prespecified Antibody Titer Level for Toxin A at Day 37 — 12.5; 68.4; 85.5 percentage of participants
Phase 2 N=43 OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye
Dry Eye
Primary: Total Corneal Fluorescein Staining — 4.09; 5.05 units on a scale
Phase 2 N=6 AUY922 for Advanced ALK-positive NSCLC
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Phase 2 N=110 Cognitive Remediation for Cocaine Dependence
Cocaine Dependence
Primary: Cocaine Use Based on Urine Drug Screening — 20.36; 15.57; 22.3; 27.8 number of negative drug screens
Phase 2 N=67 Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Leukemia · Lymphoma
Primary: Objective Response Rate — 2; 4; 6; 17 Participants
Phase 2 N=42 Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Myotonic Dystrophy
Primary: Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance — 17.44; 7.25 Meters
Phase 2 N=78 Nitric Oxide to Treat Pulmonary Embolism
Pulmonary Embolism
Primary: Number of Participants With Normal Right Ventricular (RV) Function and Viability — 9; 5 Participants
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 2 N=60 A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
Multicentric Castleman's Disease
Primary: Number of Participants With Adverse Events (AEs) — 60 Participants
Phase 2 N=90 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
Colorectal Cancer
Primary: 3-Year Disease-free Survival — 88.2 percentage of patients
Phase 2 N=108 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001
Phase 2 N=48 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma · Mantle Cell Lymphoma · Burkitt's Lymphoma
Primary: Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) — 25; 23; 40; 100 percentage of participants
Phase 2 N=360 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
Healthy
Primary: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) (Diary-Recorded) Following Either Vaccination Dose by Severity — 7; 0; 14; 3 participants
Phase 2 N=45 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Diffuse Large B-Cell Lymphoma · Transformed Follicular Lymphoma · Mantle Cell Lymphoma
Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants